Skip to main content
OpenTrials
Completed

NCT Number: NCT00408421

Duloxetine Versus Placebo for Osteoarthritis Knee Pain

The primary purpose of this study is to determine if duloxetine reduces pain severity in patients with osteoarthritis knee pain.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Osteoarthritis Knee Pain

Age range

40 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hato Rey, Puerto Rico

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female outpatients with osteoarthritis knee pain.

Exclusion criteria

  • Cardiovascular, hepatic, renal, respiratory, or hematologic illness, or other medical or psychiatric condition that, in the opinion of the investigator, would compromise participation or be likely to lead to hospitalization during the course of the study.
  • Acute liver injury (such as hepatitis) or severe cirrhosis.
  • Previous exposure to duloxetine.
  • Body Mass Index (BMI) over 40.
  • Major depressive disorder.
  • Daily use of narcotics.

Treatment and study plan

Duloxetine

Drug

Other names: LY248686, Cymbalta

Placebo

Drug

Primary outcomes

  1. Weekly Change From Baseline in the 24-Hour Average Pain Rating Using an 11-Point Numerical Likert Scale Patient Diary

    Time frame: Over 13 Weeks

    This is an ordinal scale assessing the 24-hour average pain with scores from 0 (no pain) to 10 (worst possible pain).

Secondary outcomes

  1. Patient Global Impression of Improvement at 13 Week Endpoint

    Time frame: 13 Weeks

    A scale that measures the patient's perception of improvement at the time of assessment. The score ranges from 1 (very much better) to 7 (very much worse).

  2. Change From Baseline to 13 Week Endpoint in Western Ontario and McMaster Osteoarthritis Index (WOMAC) - Pain Subscale

    Time frame: Baseline and 13 Weeks

    The WOMAC index (pain, stiffness, physical function subscales) will be completed by the patient. The pain subscale has 5 questions on pain associated with every day tasks. Each question is answered using a 5-point Likert scale (0 to 4). The pain subscale has a range of scores of 0 (none) to 20 (extreme).

  3. Change From Baseline to 13 Week Endpoint in Western Ontario and McMaster Osteoarthritis Index (WOMAC) - Stiffness Subscale

    Time frame: Baseline and 13 Weeks

    The WOMAC index (pain, stiffness, physical function subscales) will be completed by the patient. The stiffness subscale has 2 questions on stiffness associated with time of day (morning versus later in the day). Each question is answered using a 5-point Likert scale (0 to 4). The pain subscale has a range of scores of 0 (none) to 8 (extreme).

  4. Change From Baseline to 13 Week Endpoint in Western Ontario and McMaster Osteoarthritis Index (WOMAC) - Physical Function Subscale

    Time frame: Baseline and 13 Weeks

    The WOMAC index (pain, stiffness, physical function subscales) will be completed by the patient. The physical function subscale has 17 questions on physical function difficulties with every day tasks. Each question is answered using a 5-point Likert scale (0 to 4). The physical function subscale has a range of scores of 0 (none) to 68 (extreme).

  5. Change From Baseline to 13 Week Endpoint in Western Ontario and McMaster Osteoarthritis Index (WOMAC) - Total Score

    Time frame: Baseline and 13 Weeks

    The WOMAC index (pain, stiffness, physical function subscales) will be completed by the patient. The index has 24 questions. Each question is answered using a 5-point Likert scale (0 to 4). The Total score has a range from 0 (none) to 96 (extreme).

  6. Change From Baseline to 13 Week Endpoint in Weekly Mean of the 24-Hour Worst Pain Score

    Time frame: Baseline and 13 Weeks

    This is an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). The value is the change from baseline in the weekly mean of the 24-hour worst pain score on the scale.

  7. Weekly Change From Baseline in the 24-Hour Worst Pain Score

    Time frame: Over 13 Weeks

    This is an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). The value is the change from baseline in the weekly mean of the 24-hour worst pain score on the scale.

  8. Change From Baseline to 13 Week Endpoint in Weekly Mean of 24-Hour Average Pain in the Re-Randomized Treatment Phase

    Time frame: Baseline and 13 Weeks

    This is an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). This value is the change from baseline in the weekly mean of the 24-hour average pain score on the scale.

  9. Change From Baseline to 13 Week Endpoint in Clinical Global Impression of Severity

    Time frame: Baseline and 13 Weeks

    Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients.

  10. Change From Baseline to 13 Week Endpoint in Brief Pain Inventory (BPI) - Worst Pain Score

    Time frame: Baseline and 13 Weeks

    A self-reported scale that measures the severity of pain based on the worst pain experienced over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).

  11. Change From Baseline to 13 Week Endpoint in Brief Pain Inventory - Least Pain Score

    Time frame: Baseline and 13 Weeks

    A self-reported scale that measures the severity of pain based on the least pain experienced over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).

  12. Change From Baseline to 13 Week Endpoint in Brief Pain Inventory - Average Pain Score

    Time frame: Baseline and 13 Weeks

    A self-reported scale that measures the severity of pain based on the average pain experienced over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).

  13. Change From Baseline to 13 Week Endpoint in Brief Pain Inventory - Pain Right Now Score

    Time frame: Baseline and 13 Weeks

    A self-reported scale that measures the severity of pain based on the pain right now. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).

  14. Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Interference Score - General Activity

    Time frame: Baseline and 13 Weeks

    A self-reported scale that measures the interference of pain in the past 24 hours on general acitivity. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).

  15. Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Interference Score - Mood

    Time frame: Baseline and 13 Weeks

    A self-reported scale that measures the interference of pain in the past 24 hours on mood. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).

  16. Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Interference Score - Walking Ability

    Time frame: Baseline and 13 Weeks

    A self-reported scale that measures the interference of pain in the past 24 hours on walking ability. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).

  17. Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Interference Score - Normal Work

    Time frame: Baseline and 13 Weeks

    A self-reported scale that measures the interference of pain in the past 24 hours on normal work. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).

  18. Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Interference Score - Relations With Other People

    Time frame: Baseline and 13 Weeks

    A self-reported scale that measures the interference of pain in the past 24 hours on relations with other people. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).

  19. Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Interference Score - Sleep

    Time frame: Baseline and 13 Weeks

    A self-reported scale that measures the interference of pain in the past 24 hours on sleep. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).

  20. Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Interference Score - Enjoyment of Life

    Time frame: Baseline and 13 Weeks

    A self-reported scale that measures the interference of pain in the past 24 hours on enjoyment of life. The Interference scores range from 0 (does not interfere) to 10 (completely interferes).

  21. Change From Baseline to 13 Week Endpoint in Brief Pain Inventory Average Interference

    Time frame: Baseline and 13 Weeks

    A self-reported scale that measures interference of pain on average of the 7 questions assessing the interference of pain for general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. The average Interference scores range from 0 (does not interfere) to 10 (completely interferes).

  22. Response to Treatment - The Number of Participants With a >= 30% Reduction of Weekly Mean in 24-Hour Average Pain Severity Ratings

    Time frame: Over 13 Weeks

    Number of participants who experienced a response to treatment, which was defined as having a >=30% reduction of the weekly mean in 24-hour average pain severity ratings. This is an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain).

  23. Response to Treatment - The Number of Participants With a >=30% Reduction of Weekly Mean in 24-Hour Average Pain Severity Ratings in the Re-Randomized Treatment Phase

    Time frame: Over 13 Weeks

    Number of participants who experienced a response to treatment, which was defined as having a >=30% reduction of the weekly mean in 24-hour average pain severity ratings. Response to treatment over the last 6 weeks of the trial (after patients were re-randomized) were compared to baseline measures.

  24. Change From Baseline to 13 Week Endpoint in Medical Outcomes Study Short Form-36 (SF-36) - Mental Health Component Summary

    Time frame: Baseline and 13 Weeks

    A self-reported questionnaire that consists of 36 questions covering 8 health domains. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale, with higher scores indicating better health status or functioning. The mental component summary (MCS) has been constructed based on the 8 SF-36 domains.

  25. Change From Baseline to 13 Week Endpoint in Medical Outcomes Study Short Form-36 (SF-36) - Physical Component Summary

    Time frame: Baseline and 13 Weeks

    A self-reported questionnaire that consists of 36 questions covering 8 health domains. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale, with higher scores indicating better health status or functioning. The physical component summary (PCS) has been constructed based on the 8 SF-36 domains.

  26. Change From Baseline to 13 Week Endpoint in Euro-Quality of Life - 5 Dimensions (EQ-5D): US Based Index Score

    Time frame: Baseline and 13 Weeks

    The EQ-5D is an assessment of one's overall health. Consists of 5 items. Patients choose 1 of 3 options that best describe the status of each item. The EQ-5D US based index scores range from -0.11 to 1.0 where a score of 1.0 indicates perfect health. A positive change from baseline indicates health improvement.

  27. Change From Baseline to 13 Week Endpoint in Beck Depression Inventory-II - Total Score

    Time frame: Baseline and 13 Weeks

    A 21-item, patient-completed questionnaire to assess characteristics of depression. Each of the 21 items corresponding to a symptom of depression is summed to give a single score. There is a four-point scale for each item ranging from 0 to 3. Total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe.

  28. Change From Baseline to 13 Week Endpoint in Hospital Anxiety and Depression Scale (HADS) - Anxiety Subscale

    Time frame: Baseline and 13 Weeks

    A 14-item questionnaire with 2 subscales: anxiety and depression. Each item is rated on a 4-point scale, giving maximum scores of 21 for anxiety and depression. Scores of 11 or more on either subscale are considered to be a significant 'case' of psychological morbidity, while scores of 8-10 represent 'borderline' and 0-7, 'normal.'

  29. Statistically Significant Change From Baseline to 13 Week Endpoint in Laboratory Data - Chemistry Analytes: Alkaline Phosphatase

    Time frame: Baseline and 13 Weeks

    Change from baseline to endpoint in alkaline phosphatase using central laboratory reference ranges.

  30. Statistically Significant Change From Baseline to 13 Week Endpoint in Laboratory Data - Chemistry Analytes: Uric Acid

    Time frame: Baseline and 13 Weeks

    Change from baseline to endpoint in uric acid using central laboratory reference ranges.

  31. Change From Baseline to 13 Week Endpoint in Vital Signs - Pulse Rate

    Time frame: Baseline and 13 Weeks

    Pulse rate (heart rate) measured in the sitting position.

  32. Change From Baseline to 13 Week Endpoint in Vital Signs - Blood Pressure (BP) Diastolic

    Time frame: Baseline and 13 Weeks

    Diastolic blood pressure measured in the sitting position.

  33. Change From Baseline to 13 Week Endpoint in Vital Signs - Blood Pressure (BP) Systolic

    Time frame: Baseline and 13 Weeks

    Systolic blood pressure measured in the sitting position.

  34. Change From Baseline to 13 Week Endpoint in Vital Signs - Weight

    Time frame: Baseline and 13 Weeks

Sponsors and collaborators

Lead sponsor

Eli Lilly and Company

Industry

Registry information

Official study title

Duloxetine 60 to 120 mg Versus Placebo in the Treatment of Patients With Osteoarthritis Knee Pain

Important dates

Study start
2006
Primary completion
2007
Study completion
2007
First posted
Dec 7, 2006
Registry last updated
Aug 19, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.